<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571463</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/483/2020</org_study_id>
    <nct_id>NCT04571463</nct_id>
  </id_info>
  <brief_title>Ethyl Glucuronide in Urine Samples of Pregnant Women Within the HUS ja PHHYKY Area</brief_title>
  <official_title>Etyyliglukuronidin Esiintyminen Virtsassa äitiysneuvola- ja äitiyspoliklinikkakäyntien yhteydessä HUS:n ja PHHYKY:n Alueella</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanna Kahila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Pediatric Neurology Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Foundation for Alcohol Studies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Päijänne Tavastia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seinajoki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to find how many women continue using alcohol during their pregnancies the plan is&#xD;
      to anonymously test routine urine samples collected during pregnancies for ethylglucuronide&#xD;
      (ETG), a metabolite of ethanol that is detectable in urine up to several days after alcohol&#xD;
      consumptions. Altogether 600 samples are taken in the prenatal care units and the prenatal&#xD;
      care units dedicated for the alcohol and drug abusing mothers both in the Helsinki and Lahti&#xD;
      areas. Test results are used to estimate and compare the prevalence of severe maternal&#xD;
      drinking in the different populations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EtG</measure>
    <time_frame>Day 1</time_frame>
    <description>The routine urine samples from the visitors are tested for ethyl glucuronide using dip sticks with 300ng cut off. Positve finds are confirmed in a laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nicotine</measure>
    <time_frame>Day 1</time_frame>
    <description>The positive EtG urine samples and random negative urine samples from the visitors are tested for nicotine using dip sticks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabis</measure>
    <time_frame>Day 1</time_frame>
    <description>The positive EtG urine samples and random negative urine samples from the visitors are tested for cannabis using dip sticks.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Fetal Alcohol Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>HUCS A</arm_group_label>
    <description>Mothers visiting the prenatal care units within the Helsinki area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HUCS HAL</arm_group_label>
    <description>Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHHYKY A</arm_group_label>
    <description>Mothers visiting the prenatal care units within the Lahti area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHHYKY HALSO</arm_group_label>
    <description>Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population for the ethylglucuronide (EtG) testing consists of the visitors in the&#xD;
        HYKS, PHHYKY and the cities of Helsinki and Lahti prenatal care units, as well as the HYKS&#xD;
        and PHHKYKY prenatal care units dedicated for the alcohol and drug abusing mothers (HAL- /&#xD;
        HALSO-poliklinikka).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Kahila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikko A Koivu-Jolma</last_name>
    <phone>+358505965442</phone>
    <email>mikko.koivu-jolma@helsinki.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>HALSO-poliklinikka</name>
      <address>
        <city>Lahti</city>
        <state>Päijät-Häme</state>
        <zip>715850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Äitiyspoliklinikka/neuvola</name>
      <address>
        <city>Lahti</city>
        <state>Päijät-Häme</state>
        <zip>715850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HAL-poliklinikka</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Äitiyspoliklinikka/neuvola</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00120</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Hanna Kahila</investigator_full_name>
    <investigator_title>Senior Ward Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Alcohol Spectrum Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected anonymized IPD and the modeling source code will be shared.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after the publication</ipd_time_frame>
    <ipd_access_criteria>Scientific study, policy making</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

